

Financial Tear Sheet

Corporate Profile

We are a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of patients' lives.

Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, [Subsys®](#), which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules.

In March 2012, we launched [Subsys®](#), our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in adult opioid-tolerant patients, through our cost-efficient commercial organization of approximately 250 sales professionals.

Since late 2014, [Subsys®](#) has been the most prescribed transmucosal immediate-release fentanyl, or TIRF, product with 48% market share on a prescription basis, according to IMS.

In December 2011, we launched Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment for chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS, through our exclusive distributor, a leading generic pharmaceutical company.

Our lead product candidate is [Dronabinol Oral Solution](#), a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved. We intend to market [Dronabinol Oral Solution](#) and any other future supportive care products, if approved, through our commercial organization.

Please see [full prescribing information](#) for [Subsys®](#) including the boxed warning.

SEC FILINGS

FILING DATE	FORM
06/14/17	4
06/02/17	4
05/26/17	4
05/18/17	4

INSYS Therapeutics, Inc.

Attn: Secretary of the Board of Directors
1333 South Spectrum Blvd, Suite 100
Chandler, AZ 85286
Phone: (602) 910-2617
Fax: (602) 910-2627

Stock Information

INSY (COMMON STOCK)	
Exchange	NASDAQ GS (US Dollar)
Price	\$12.77
Change (%)	▼ 0.45 (3.40%)
Volume	65,974
52 Week Low	\$8.70
Market Cap	\$953,496,744
Rolling EPS	-0.02
PE Ratio	0
Shares Outstanding	72,125,321
Data as of 06/27/17 12:38 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

DATE	TITLE
06/20/17	Insys Therapeutics Hires Four Key Pharmaceutical Industry Veterans for Leadership Positions
06/05/17	Insys Therapeutics, Inc. Releases Statement on Its Ongoing Mission
05/31/17	Insys Therapeutics, Inc. to Present at June Conferences

Upcoming Events

There are currently no events scheduled.

Ownership Profile

SHAREHOLDERS				
	Holders	Value (\$MM)	% O/S	Shares
Institution	186	750.13	96.6	69,703,532
Mutual Fund	191	125.58	12.0	8,654,174
Insider *	9	2.20	0.3	179,388

*Insider values reflect direct beneficial ownership.

TOP HOLDERS				
	Shares Held	% O/S	Share Change	Filing Date
John N. Kapoor Trust	42,430,310	58.8	55,700	03/15/17
OrbiMed Advisors, LLC	6,071,440	8.4	0	03/31/17
Kapoor Children's 1992 Trust	4,557,950	6.3	0	03/15/17
BlackRock Institutional Trust Company, N.A.	2,425,579	3.4	-12,030	03/31/17
The Vanguard Group, Inc.	2,351,107	3.3	-29,785	03/31/17
Kapoor (John N)	1,180,368	1.6	0	03/15/17
Folger Hill Asset Management LLC	1,006,261	1.4	-228,228	03/31/17
APG Asset Management	835,244	1.2	49,857	12/31/15
Dimensional Fund Advisors, L.P.	569,512	0.8	-3,152	03/31/17
Invesco PowerShares Capital Management LLC	518,698	0.7	-6,010	03/31/17